查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1376144

勃起功能障礙治療藥物市場規模、佔有率、趨勢分析報告：按產品、地區和細分市場分類的趨勢，2023-2030 年

Erectile Dysfunction Drugs Market Size, Share & Trends Analysis Report By Product (Viagra, Cialis, Zydena, Levitra, Stendra, Others), By Region (North America, Europe, APAC, Latin America, MEA), And Segment Forecasts, 2023 - 2030
出版日期: | 出版商: Grand View Research | 英文 79 Pages | 商品交期: 2-10個工作天內

價格

勃起功能障礙治療藥物市場成長與趨勢：

Grand View Research, Inc. 的一項新研究顯示，到 2030 年，全球勃起功能障礙藥物市場預計將達到 47.9 億美元。

預計2023年至2030年該市場將以8.8%的年複合成長率擴張。勃起功能障礙盛行率的增加預計將有助於市場成長。根據歐洲泌尿系統協會的數據，2020 年歐洲 40-70 歲男性族群中 ED 的總體盛行率約為 52%。根據波士頓大學醫學院的數據，大約 22.0% 的 40 多歲男性和 49.0% 的 70 多歲男性患有勃起功能障礙。因此，預計在預測期內，老年人口的增加將增加 ED 的盛行率，並有望為市場創造有利的成長機會。

禮來公司透過禮來患者支持計劃 (LPSP) 提供低成本藥物來幫助 ED 患者。該計劃為加拿大合格的未投保 ED 患者提供經濟援助，並且該計劃可能需要註冊。因此，犀利士品牌版中此類援助計畫的存在可能會讓低收入患者更負擔得起，也可能導致收益增加。此外，公司也採取聯盟和夥伴關係等配合措施，在國外市場製造和商業化產品。例如，2022 年 1 月，Petros Pharmaceuticals, Inc. 與全球受託製造廠商(CDMO) 合作，進行阿伐那非錠劑的商業生產。此次合作旨在取代與 Vivas 的現有合約並提供持續的產品供應。

此外，根據國家醫學圖書館（2021）的數據，四川海絲古藥業有限公司在中國當地的ED 患者中進行了一項評估 Stendra 安全性和有效性的 3 期臨床試驗。臨床試驗結果顯示，兩種給藥的 Stendra 100mg 和 200mg 對中國 ED 患者的治療效果有所改善。這項臨床療效的證明可能會加強 Strenda (Avanafil) 的市場地位。然而，對勃起功能障礙缺乏認知、對治療感到羞恥、誤診、圍繞疾病的社會恥辱、缺乏謹慎等可能會抑制市場成長。根據歐洲泌尿系統協會（EAU）的一項調查，只有18%的西班牙人聽說過ED治療，而68.0%的人相信其有效性。

勃起功能障礙治療藥物市場報告亮點

  • 按產品分類，由於威而鋼在全球範圍內的供應以及 ED 患者對該產品的認知度不斷提高，威而鋼部門市場在 2022 年佔據了最大的市場佔有率。
  • 北美主導勃起功能障礙藥物市場，2022 年銷售佔有率為 51.3%。這是由於該地區疾病負擔高、醫療基礎設施強大以及新治療產品的快速核准。
  • 預計亞太地區在預測期內將以 10.2% 的年複合成長率成長最快。該地區的成長得益於新產品的進入該地區。

目錄

第1章 調查方法和範圍

第2章 執行摘要

第3章 勃起功能障礙治療藥物市場變數、趨勢與範圍

  • 市場體系展望
  • 普及和成長前景圖
  • 市場動態
    • 市場促進因素分析
    • 市場抑制因素分析
  • 勃起功能障礙藥物市場分析工具
    • 產業分析-波特五力分析
    • PESTEL分析

第4章 勃起功能障礙治療藥物市場：產品評估與趨勢分析

  • 勃起功能障礙藥物市場：重點
  • 勃起功能障礙藥物市場：2022 年和 2030 年產品趨勢和市場佔有率分析
  • 威而鋼
  • 犀利士
  • 齊德納
  • 萊維特拉
  • 斯滕德拉
  • 其他

第5章 勃起功能障礙治療藥物市場：區域估計和趨勢分析

  • 區域展望
  • 按地區分類的勃起功能障礙藥物市場：要點
  • 北美洲
    • 2018-2030 年市場估計與預測
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 瑞典
    • 挪威
    • 丹麥
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 泰國
    • 韓國
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中東/非洲
    • 沙烏地阿拉伯
    • 南非
    • 阿拉伯聯合大公國
    • 科威特

第6章 競爭形勢

  • 主要市場參與企業的最新趨勢和影響分析
  • 市場參與企業分類
    • Pfizer, Inc.
    • Eli Lilly and Company
    • Teva Pharmaceutical Industries Ltd.
    • Sanofi
    • Sun Pharmaceutical Industries Ltd.
    • Bayer AG
    • Petros Pharmaceuticals, Inc.
    • VIVUS, Inc.
    • Auxilium Pharmaceuticals
    • Adamed
    • Cipla Inc.
Product Code: 978-1-68038-604-2

Erectile Dysfunction Drugs Market Growth & Trends:

The global erectile dysfunction drugs market size is expected to reach USD 4.79 billion by 2030, according to a new study by Grand View Research, Inc.. The market is expected to expand at a CAGR of 8.8% from 2023 to 2030. The increasing prevalence of erectile dysfunction is expected to contribute to market growth. According to the European Association of Urology, the overall prevalence of ED was found to be around 52% in the European male population aged 40-70 years in 2020. In addition, according to the Boston University School of Medicine, approximately 22.0% of 40 years aged male population and 49.0% by age of 70 years are affected by erectile dysfunction. Thus, the increasing geriatric population is anticipated to increase the prevalence of ED over the forecast period and is expected to create lucrative growth opportunities in the market.

Eli Lilly and Company is supporting ED patients by offering medicine at low cost through Lilly Patient Support Program (LPSP). This program provides financial assistance to eligible ED uninsured patients in Canada who may require registration for this program. Thus, the presence of such supportive programs for a branded version of Cialis may increase the affordability of the lower-income patient population and also aid in generating increased revenue. Moreover, companies have undertaken initiatives such as collaboration and partnership for the manufacturing and commercialization of products in the overseas market. For instance, in January 2022, Petros Pharmaceuticals Inc. partnered with a global Contract Manufacturing Organization (CDMO) for the commercial production of Avanafil tablets. This partnership was formed with an aim to replace the existing agreement with Vivus Inc. and continue product supply.

Furthermore, according to the National Library of Medicine (2021), a phase 3 clinical trial was conducted by Sichuan Haisco Pharmaceutical Co., Ltd. to evaluate the safety and efficacy of Stendra in patients with ED in mainland China. The results of the clinical trial showed improvement in Chinese ED patients after administration of two doses of Stendra 100 mg & 200 mg. Such proven clinical effectiveness may strengthen Strenda's (Avanafil) position in the market. However, lack of awareness about erectile dysfunction, shame about treatment, false-positive beliefs, social stigma pertaining to the disease, and lack of discretion may restrain the market growth. As per the survey conducted by the European Association of Urology (EAU), only 18% of the Spanish population heard about ED treatment, whereas 68.0% of the population believes the treatment benefits.

Erectile Dysfunction Drugs Market Report Highlights:

  • By product, the viagra segment held the largest market share in 2022 due to the worldwide availability of Viagra and increased awareness about the product among ED patients
  • North America dominated the erectile dysfunction drugs market and accounted for a revenue share of 51.3% in 2022, due to the high burden of disease, strong healthcare infrastructure, and rapid approval of new products for treatment in the region.
  • Asia Pacific is expected to advance at the fastest CAGR of 10.2% during the forecast period. The growth of the region is attributable to the entry of new products into the region.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Product
    • 1.1.2. Regional scope
    • 1.1.3. Estimates and forecast timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
  • 1.4. Information or Data Analysis
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Product outlook
    • 2.2.2. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Erectile Dysfunction Drugs Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Market Dynamics
    • 3.3.1. Market driver analysis
    • 3.3.2. Market restraint analysis
  • 3.4. Erectile Dysfunction Drugs Market Analysis Tools
    • 3.4.1. Industry Analysis - Porter's Five Forces
      • 3.4.1.1. Supplier power
      • 3.4.1.2. Buyer power
      • 3.4.1.3. Substitution threat
      • 3.4.1.4. Threat of new entrant
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Technological landscape
      • 3.4.2.3. Economic landscape

Chapter 4. Erectile Dysfunction Drugs Market: Product Estimates & Trend Analysis

  • 4.1. Erectile Dysfunction Drugs Market: Key Takeaways
  • 4.2. Erectile Dysfunction Drugs Market: Product Movement & Market Share Analysis, 2022 & 2030
  • 4.3. Viagra
    • 4.3.1. Viagra market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.4. Cialis
    • 4.4.1. Cialis market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.5. Zydena
    • 4.5.1. Zydena market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.6. Levitra
    • 4.6.1. Levitra market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.7. Stendra
    • 4.7.1. Stendra market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.8. Others
    • 4.8.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. Erectile Dysfunction Drugs Market: Regional Estimates & Trend Analysis

  • 5.1. Regional Outlook
  • 5.2. Erectile Dysfunction Drugs Market by Region: Key Takeaways
  • 5.3. North America
    • 5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.3.2. U.S.
      • 5.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.3.3. Canada
      • 5.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 5.4. Europe
    • 5.4.1. UK
      • 5.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.4.2. Germany
      • 5.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.4.3. France
      • 5.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.4.4. Italy
      • 5.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.4.5. Spain
      • 5.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.4.6. Sweden
      • 5.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.4.7. Norway
      • 5.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.4.8. Denmark
      • 5.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 5.5. Asia Pacific
    • 5.5.1. Japan
      • 5.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.5.2. China
      • 5.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.5.3. India
      • 5.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.5.4. Australia
      • 5.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.5.5. Thailand
      • 5.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.5.6. South Korea
      • 5.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 5.6. Latin America
    • 5.6.1. Brazil
      • 5.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.6.2. Mexico
      • 5.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.6.3. Argentina
      • 5.6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 5.7. MEA
    • 5.7.1. Saudi Arabia
      • 5.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.7.2. South Africa
      • 5.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.7.3. UAE
      • 5.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.7.4. Kuwait
      • 5.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

Chapter 6. Competitive Landscape

  • 6.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 6.2. Market Participant Categorization
    • 6.2.1. Pfizer, Inc.
      • 6.2.1.1. Company overview
      • 6.2.1.2. Financial performance
      • 6.2.1.3. Product benchmarking
      • 6.2.1.4. Strategic initiatives
    • 6.2.2. Eli Lilly and Company
      • 6.2.2.1. Company overview
      • 6.2.2.2. Financial performance
      • 6.2.2.3. Product benchmarking
      • 6.2.2.4. Strategic initiatives
    • 6.2.3. Teva Pharmaceutical Industries Ltd.
      • 6.2.3.1. Company overview
      • 6.2.3.2. Financial performance
      • 6.2.3.3. Product benchmarking
      • 6.2.3.4. Strategic initiatives
    • 6.2.4. Sanofi
      • 6.2.4.1. Company overview
      • 6.2.4.2. Financial performance
      • 6.2.4.3. Product benchmarking
      • 6.2.4.4. Strategic initiatives
    • 6.2.5. Sun Pharmaceutical Industries Ltd.
      • 6.2.5.1. Company overview
      • 6.2.5.2. Financial performance
      • 6.2.5.3. Product benchmarking
      • 6.2.5.4. Strategic initiatives
    • 6.2.6. Bayer AG
      • 6.2.6.1. Company overview
      • 6.2.6.2. Financial performance
      • 6.2.6.3. Product benchmarking
      • 6.2.6.4. Strategic initiatives
    • 6.2.7. Petros Pharmaceuticals, Inc.
      • 6.2.7.1. Company overview
      • 6.2.7.2. Financial performance
      • 6.2.7.3. Product benchmarking
      • 6.2.7.4. Strategic initiatives
    • 6.2.8. VIVUS, Inc.
      • 6.2.8.1. Company overview
      • 6.2.8.2. Financial performance
      • 6.2.8.3. Product benchmarking
      • 6.2.8.4. Strategic initiatives
    • 6.2.9. Auxilium Pharmaceuticals
      • 6.2.9.1. Company overview
      • 6.2.9.2. Financial performance
      • 6.2.9.3. Product benchmarking
      • 6.2.9.4. Strategic initiatives
    • 6.2.10. Adamed
      • 6.2.10.1. Company overview
      • 6.2.10.2. Financial performance
      • 6.2.10.3. Product benchmarking
      • 6.2.10.4. Strategic initiatives
    • 6.2.11. Cipla Inc.
      • 6.2.11.1. Company overview
      • 6.2.11.2. Financial performance
      • 6.2.11.3. Product benchmarking
      • 6.2.11.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviations
  • Table 2 North America erectile dysfunction drugs market, by product, 2018 - 2030 (USD Million)
  • Table 3 North America erectile dysfunction drugs market, by region, 2018 - 2030 (USD Million)
  • Table 4 U.S. erectile dysfunction drugs market, by product, 2018 - 2030 (USD Million)
  • Table 5 Canada erectile dysfunction drugs market, by product, 2018 - 2030 (USD Million)
  • Table 6 Europe erectile dysfunction drugs market, by product, 2018 - 2030 (USD Million)
  • Table 7 Europe erectile dysfunction drugs market, by region, 2018 - 2030 (USD Million)
  • Table 8 Germany erectile dysfunction drugs market, by product, 2018 - 2030 (USD Million)
  • Table 9 UK erectile dysfunction drugs market, by product, 2018 - 2030 (USD Million)
  • Table 10 France erectile dysfunction drugs market, by product, 2018 - 2030 (USD Million)
  • Table 11 Italy erectile dysfunction drugs market, by product, 2018 - 2030 (USD Million)
  • Table 12 Spain erectile dysfunction drugs market, by product, 2018 - 2030 (USD Million)
  • Table 13 Sweden erectile dysfunction drugs market, by product, 2018 - 2030 (USD Million)
  • Table 14 Norway erectile dysfunction drugs market, by product, 2018 - 2030 (USD Million)
  • Table 15 Denmark erectile dysfunction drugs market, by product, 2018 - 2030 (USD Million)
  • Table 16 Asia Pacific erectile dysfunction drugs market, by product, 2018 - 2030 (USD Million)
  • Table 17 Asia Pacific erectile dysfunction drugs market, by region, 2018 - 2030 (USD Million)
  • Table 18 Japan erectile dysfunction drugs market, by product, 2018 - 2030 (USD Million)
  • Table 19 China erectile dysfunction drugs market, by product, 2018 - 2030 (USD Million)
  • Table 20 India erectile dysfunction drugs market, by product, 2018 - 2030 (USD Million)
  • Table 21 Australia erectile dysfunction drugs market, by product, 2018 - 2030 (USD Million)
  • Table 22 Thailand erectile dysfunction drugs market, by product, 2018 - 2030 (USD Million)
  • Table 23 South Korea erectile dysfunction drugs market, by product, 2018 - 2030 (USD Million)
  • Table 24 Latin America erectile dysfunction drugs market, by product, 2018 - 2030 (USD Million)
  • Table 25 Latin America erectile dysfunction drugs market, by region, 2018 - 2030 (USD Million)
  • Table 26 Brazil erectile dysfunction drugs market, by product, 2018 - 2030 (USD Million)
  • Table 27 Mexico erectile dysfunction drugs market, by product, 2018 - 2030 (USD Million)
  • Table 28 Argentina erectile dysfunction drugs market, by product, 2018 - 2030 (USD Million)
  • Table 29 Middle East and Africa erectile dysfunction drugs market, by product, 2018 - 2030 (USD Million)
  • Table 30 Middle East and Africa erectile dysfunction drugs market, by region, 2018 - 2030 (USD Million)
  • Table 31 South Africa erectile dysfunction drugs market, by product, 2018 - 2030 (USD Million)
  • Table 32 Saudi Arabia erectile dysfunction drugs market, by product, 2018 - 2030 (USD Million)
  • Table 33 UAE erectile dysfunction drugs market, by product, 2018 - 2030 (USD Million)
  • Table 34 Kuwait erectile dysfunction drugs market, by product, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Erectile dysfunction drugs: Market outlook
  • Fig. 9 Erectile dysfunction drugs: Competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 Industry value chain analysis
  • Fig. 14 Erectile dysfunction drugs market driver impact
  • Fig. 15 Erectile dysfunction drugs market restraint impact
  • Fig. 16 Erectile dysfunction drugs market strategic initiatives analysis
  • Fig. 17 Erectile dysfunction drugs market: Product movement analysis
  • Fig. 18 Erectile dysfunction drugs market: Product outlook and key takeaways
  • Fig. 19 Viagra market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 20 Cialis market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 21 Zydena market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 22 Levitra market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 23 Stendra market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 24 Others market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 25 Global erectile dysfunction drugs market: Regional movement analysis
  • Fig. 26 Global erectile dysfunction drugs market: Regional outlook and key takeaways
  • Fig. 27 North America market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 28 U.S. market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 29 Canada market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 30 Europe market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 31 UK market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 32 Germany market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 33 France market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 34 Italy market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 35 Spain market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 36 Sweden market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 37 Norway market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 38 Denmark market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 39 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 40 Japan market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 41 China market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 42 India market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 43 Australia market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 44 Thailand market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 45 South Korea market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 46 Latin America market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 47 Brazil market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 48 Mexico market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 49 Argentina market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 50 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 51 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 52 South Africa market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 53 UAE market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 54 Kuwait market estimates and forecasts, 2018 - 2030 (USD million)